SOLO: 48-Week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

AIDS

Volumn 18, Issue 11, 2004, Pages 1529-1537

  Gathe Jr , Joseph C ^a   Ive, Prudence ^b   Wood, Robin ^c   Schürmann, Dirk ^d   Bellos, Nicholaos C ^e   DeJesus, Edwin ^f   Gladysz, Andrzej ^g   Garris, Cindy ^h   Yeo, Jane ⁱ  

^a Therapeutic Concepts   (United States)

^b Clinical HIV Research Unit   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e SW Infectious Disease Associates ^*  (United States)

^f IDC Research Initiative   (United States)

^g UNIVERSITY OF WROC AW   (Poland)

^h GLAXOSMITHKLINE   (United States)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Fosamprenavir; HIV 1; Nelfinavir; Protease inhibitor; Ritonavir; SOLO

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; CD4 ANTIGEN; LAMIVUDINE; LIVER ENZYME; NELFINAVIR; RITONAVIR; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IC 50; LIPID BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SIDE EFFECT; TREATMENT FAILURE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIREMIA;

ADOLESCENT; ADULT; AGED; CARBAMATES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; PATIENT COMPLIANCE; PHOSPHORIC ACID ESTERS; RITONAVIR; SULFONAMIDES;

EID: 3843151487     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131332.30548.92     Document Type: Article

References (32)

1. Johnson M, Curtis H. BHIVA national clinical audit of ART. British HIV Association website. http://www.bhiva.org.
2. Epidemiologisches Bulletin Robert Koch Institut. HIV-Infection and AIDS-Diseases in Germany. Recent Epidemiological Data (As of 31.12.2002) Report II/2002 of the Robert Koch-Institut.
3. Wood R, Aresteh K, Stellbrink H-J, Teofilo E, Raffi F, Pollard R, et al. A 6-week randomized controlled trial to compare the tolerability, pharmacokinetics and antiviral activity of GW433908 and amprenavir in HIV-1 infected subjects. Antimicrob Agents Chemother 2004; 48:116-123
4. Rodriguez-French A, Boghossian J, Gray CE, Nadler JP, Quinones AR, Sepulveda GE, et al. The NEAT study: a 48-week open label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1 infected patients. J Acquir Immune Defic Syndr 2004; 35:22-32
5. DeJesus E, Lamarca A, Sension M, Beltran C, Yeni P. The CONTEXT study: efficacy and safety of GW433908/RTV in PI experienced subjects with virological failure-24week results. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, 2003 [abstract 178].
6. Wire MB, Ballow C, Preston S, Hendrix CW, Piliero P, Lou Y, et al. Pharmacokinetics and Safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS, 2004; 18:897-907.
7. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002; 46 746-754.
8. Centres for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report. 2000; Available at http://www.cdc.gov/hiv/ stats/hasr1202.htm.
9. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein D. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001; 15:1009-1018.
10. Petropoulus CJ, Parkin NT, Limoli KL, Lie YL, Wrin T, Huang W, et al. A novel drug susceptibility assay for HIV-1. Antimicrob Agents Chemother 2000; 44:920-928
11. Anon. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
12. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Counsel 2002; 46:93-108.
13. Chaisson RE, Keruly JC, Moore RD. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA 2000; 284:3128-3129
14. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to baseline CD4 cell count and viral load. JAMA 2001; 286:2560-2567.
15. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected subjects starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
16. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-766.
17. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic guided therapy: pharmacological data from the Viradapt study. AIDS 2000; 14:1333-1339.
18. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002. JAMA 2002; 288:222-235.
19. Richman DD, Bozzette S, Morton S, Chien T, Wrin T, Dawson K, et al. The prevalence of antiretroviral drug resistance in the US. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001 [abstract LB17].
20. Viracept (nelfinavir mesylate) Product Information. La Jolla, CA: Agouron Pharmaceuticals; April 2003
21. Bekker LG, Orrell C, Reader L, Cohen K, Matoti K, Martell R, et al. Antiretroviral therapy in a community clinic: early lessons from a pilot project. S Afric Med J 2003; 93:458-462.
22. Squires KE, Thiry A, Giordano M. Atazanavir (ATV) qd and efavirenz (EFV) qd with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 48 (AI424-034). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002 [abstract H-1076].
23. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
24. Robbins G, De Gruttola V, Shafer R, Smeaton L, Snyder S, Pettinelli C, et al. Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N Engl J Med 2003; 349:2293-2303.
25. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32:18-29.
26. Kempf D, King M, Bauer J, Moseley J, Bernstein B, Brun S, et al. Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonavir or nelfinavir as initial therapy. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, 2003 [abstract 600].
27. MacManus S, Yates PJ, White S, Richards N, Snowden W. GW433908 in ART naïve subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, 2003 [poster 598].
28. MacManus S, Yates P, White S, Richards N, Snowden W, Tisdale M, et al. Lack of resistance to boosted 908 confirmed through 48 weeks of therapy in naïve subjects. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, 2003 [poster 0558].
29. MacManus S, Yates P, Elston R, White S, Richards N, Snowden W. GW433908/r Once-daily in antiretroviral therapy-naive HIV-infected subjects: absence of protease resistance at 48 weeks. AIDS, 2004; 18:651-655.
30. Hetheringtoh S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
31. Hernandez J, Cutrell A, Bonny T, Castillo S, Brothers C, Hee J, et al. Diagnosis of abacavir hypersensitivity reactions among patients not receiving abacavir in two blinded studies. Fifth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, France, 2003 [abstract 134].
32. Horban A, Staszewski S, Walmsley S, Pierone G, Sexton A, Stark T, et al. Favourable increase in high density lipo-protein cholesterol (HDL-C) concentrations in chronic HIV-infected therapy naïve subjects receiving 908/r QD in the Solo study. Ninth European AIDS Conference, Warsaw, 2003 [abstract F8/3].